Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$33.17 +2.00%

+$0.69 today

Market cap
$6.86B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.91M

Average 1.84M

IMVT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Immunovant, Inc.NASDAQ: IMVT

Net Income · Q2 FY2027 · quarter ended Sep 2026

Net income dips below year-ago levels

Q2 FY2027 net income of $97.25M (cash outflow) fell 23.1% year over year, behind the +9.5% change in trailing-twelve-month net income. Sequentially, it fell 36.5% from the prior quarter. Over 3 fiscal years it compounded at +33.8% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2026 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$551.88M (+9.2%) for the fiscal year ending Mar 2027, a slowdown from the +22.2% reported in FY2026.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$97.25M-36.5% QoQ
Last fiscal yearMar 2026
-$505.61M+22.2% YoY
LTMSep 2026
-$508.96M+9.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.1%+20.6%+43.7 pp
1 year+22.2%+9.2%-13.0 pp
3-year CAGR+33.8%-55.3%-89.1 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2026
(505.61M) USD
Year-over-year change
-22.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How IMVT compares with its peers on the latest reported figures

  • IMVT's LTM Sep 2026 net income of $508.96M is the largest of the 11 companies compared; the peer median is $135.19M.
  • Its year-over-year change of +9.5% is the 6th highest of 11, against a peer median of +12.8%.
  • Net income amounts to 7173.5% of revenue for IMVT, versus a peer median of 36.8%.
IMVT Competitors Peer median
Net Income for IMVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$508.96M +9.5%+33.8%7173.5%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$425.15M +161.2%+46.8%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$221.04M +23.7%——
ANNXAnnexon, Inc.LTM Mar 2026$196.48M +17.4%+13.3%—
CABACabaletta Bio, Inc.LTM Mar 2026$175.43M +38.4%+46.9%—
TRAXFirst Tracks Biotherapeutics IncFY2025$166.09M +1.5%——
TGTXTG Therapeutics, Inc.LTM Sep 2026$106.06M -76.3%—11.8%
IMUXImmunic, Inc.LTM Mar 2026$104.29M +8.2%-6.9%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M -46.5%-9.3%832.6%
QTTBQ32 Bio Inc.LTM Mar 2026$33.24M +155.6%—61.9%
ANABAnaptysBio, Inc.LTM Mar 2026$26.79M -81.0%—11.5%
Peer median (excluding IMVT) $135.19M+12.8%+13.3%36.8%

Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Depreciation & Amortization126K193K231K377K409K
Deferred Income Tax00000
Stock-Based Compensation34.24M32.3M41.12M49.49M55.72M
Change in Working Capital15.14M(10.85M)2.63M(12.03M)42.06M
Accounts Receivables(11.72M)12.23M(4.56M)2.97M(1.4M)
Inventory00000
Accounts Payables16.25M(17.12M)5.78M10.68M(10.25M)
Other Working Capital10.61M(5.95M)1.41M(25.69M)53.72M
Other Non-Cash Items1.11M1.13M1.13M133K99K
Operating Cash Flow(106.11M)(188.19M)(214.23M)(375.87M)(407.31M)
Capital Expenditures(254K)(197K)(360K)(759K)(8K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(254K)(197K)(360K)(759K)(8K)
Debt Repayment00000
Common Stock Issued129K70.5M472.75M450M596.26M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities200M385K(318K)4.49M(504K)
Financing Cash Flow200.13M70.89M472.43M454.49M595.76M
Effect of Forex Changes(92K)220K993K747K(299K)
Net Change in Cash93.67M(117.29M)258.83M78.61M188.14M
Free Cash Flow(106.37M)(188.39M)(214.59M)(376.63M)(407.32M)

Immunovant, Inc.

NASDAQ:IMVT

Intrinsic Alpha fair value

Locked

Current Price

$33.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.